Notably, based on WHO 2017 this entity comprised cases with biallelic CEBPA mutations (n = 56), WHO 2022 additionally considered single CEBPA mutations located in bZIP region (n = 61; in our cohort all with biallelic mutation; 5 additional biallelic CEBPA mutated cases were former AML-MRC due to differences in entity hierarchy) and ICC only included in-frame bZIP mutations (n = 47). Here, CEBPA is linked to intrahepatic cholangiocarcinoma.